Pyrroloquinoline quinone attenuates cachexia-induced muscle atrophy via suppression of reactive oxygen species
Author(s) -
Tongtong Xu,
Xiaoming Yang,
Changyue Wu,
Jiaying Qiu,
Qingqing Fang,
Lingbin Wang,
Shu Yan Yu,
Hualin Sun
Publication year - 2018
Publication title -
journal of thoracic disease
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2018.04.112
Subject(s) - myogenesis , muscle atrophy , cachexia , atrophy , medicine , reactive oxygen species , endocrinology , skeletal muscle , myocyte , myostatin , c2c12 , wasting , chemistry , cancer research , biochemistry , cancer
Cachexia, a wasting syndrome, is most commonly observed in individuals with advanced cancer including lung cancer, esophageal cancer, liver cancer, etc. The characteristic sign of cachexia is muscle atrophy. To date, effective countermeasures have been still deficiency to alleviate muscle atrophy. Reactive oxygen species (ROS) are important regulators of muscle atrophy. Therefore, the effects of a naturally antioxidant, pyrroloquinoline quinone (PQQ), were explored on muscle atrophy induced by cachexia in the present study.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom